biostudies-literatureUnknown118Kuhre RENovo Nordisk<h4>Background</h4>Amycretin is a novel unimolecular glucagon-like peptide-1 (GLP-1) and amylin receptor agonist. This study aimed to determine its role in mitigating diet-induced metabolic disorders, such as obesity, insulin resistance, and fatty liver disease, in mice and rats.<h4>Methods</h4>Preclinical studies were conducted to characterise amycretin activation of GLP-1, amylin and calcitonin receptors, and determine the effects of amycretin administration on the metabolic health of mice and rats. Investigations included measurements of body weight and body composition, energy intake and energy expenditure, insulin sensitivity, metabolic dysfunction-associated steatotic liver disease (MASLD), and access in the mouse brain.<h4>Findings</h4>Amycretin activated human, mouse and rat GLP-1,EBioMedicine105862https://www.ebi.ac.uk/biostudies/studies/S-EPMC12309853biostudies-literatureThe effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats.PMC12309853Ipsen DHLundh SHjollund KRMadsen KGHogendorf WFJRaun KSecher ABallarin-Gonzalez BPetersen SBBrand CLGlendorf TKruse TVegge AKuhre REfalseThe effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats.<h4>Background</h4>Amycretin is a novel unimolecular glucagon-like peptide-1 (GLP-1) and amylin receptor agonist. This study aimed to determine its role in mitigating diet-induced metabolic disorders, such as obesity, insulin resistance, and fatty liver disease, in mice and rats.<h4>Methods</h4>Preclinical studies were conducted to characterise amycretin activation of GLP-1, amylin and calcitonin receptors, and determine the effects of amycretin administration on the metabolic health of mice and rats. Investigations included measurements of body weight and body composition, energy intake and energy expenditure, insulin sensitivity, metabolic dysfunction-associated steatotic liver disease (MASLD), and access in the mouse brain.<h4>Findings</h4>Amycretin activated human, mouse and rat GLP-1,2025-01-01T00:00:00Z2025 Jul2026-03-27T15:28:59.059Z2025-08-24T03:06:52.178ZS-EPMC123098534070644610.1016/j.ebiom.2025.105862